Opioid-Involved Overdose Vulnerability in Wyoming: Measuring Risk in a Rural Environment

Reference

• Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020). Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). PloS One, 15(1), e0227966. https://doi.org/10.1371/journal.pone.0227966
   PubMed Web of Science ®Google Scholar
• Amiri, S., Lutz, R., Socías, M. E., McDonell, M. G., Roll, J. M., & Amram, O. (2018). Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. Journal of Substance Abuse Treatment, 93, 26–30. https://doi.org/10.1016/j.jsat.2018.07.006
   PubMed Web of Science ®Google Scholar
• Andrilla, C. H. A., Moore, T. E., & Patterson, D. G. (2019). Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 35(1), 113–121. https://doi.org/10.1111/jrh.12328
   PubMed Web of Science ®Google Scholar
• Beardsley, K., Wish, E. D., Fitzelle, D. B., O’Grady, K., & Arria, A. M. (2003). Distance traveled to outpatient drug treatment and client retention. Journal of Substance Abuse Treatment, 25(4), 279–285. https://doi.org/10.1016/S0740-5472(03)00188-0
   PubMed Web of Science ®Google Scholar
• Becker, W. C., & Fiellin, D. A. (2020). When epidemics collide: Coronavirus disease 2019 (COVID-19) and the opioid crisis. Annals of Internal Medicine, 173(1), 59–60. https://doi.org/10.7326/M20-1210
   PubMed Web of Science ®Google Scholar
• Beetham, T., Saloner, B., Wakeman, S. E., Gaye, M., & Barnett, M. L. (2019). Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality. Annals of Internal Medicine, 171(1), 1–9. https://doi.org/10.7326/M18-3457
   PubMed Web of Science ®Google Scholar
• Cabreros, I., Griffin, B. A., Saloner, B., Gordon, A. J., Kerber, R., & Stein, B. D. (2021). Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. Drug and Alcohol Dependence, 228, 109089. https://doi.org/10.1016/j.drugalcdep.2021.109089
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, National Center for Health Statistics. (n.d.). Wide-ranging online data for epidemiologic research (WONDER). Retrieved from http://wonder.cdc.gov.
   Google Scholar
• Centers for Disease Control and Prevention. National Center for Heath Statistics. (2020). CDC WONDER Online Database, Multiple Cause of Death Files. Retrieved January 6, 2022, from http://wonder.cdc.gov/mcd-icd10-expanded.html
   Google Scholar
• Centers for Disease Control and Prevention. (2019). 2019 annual surveillance report of drug-related risks and outcomes — United States surveillance special report. Retrieved July 29, 2020, from https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillancereport.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. (2020). Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic, CDCHAN-00438. Health Alert Network (HAN). Retrieved August 5, 2021, from https://emergency.cdc.gov/han/2020/han00438.asp
   Google Scholar
• Centers for Disease Control and Prevention. (2021). U.S. State Opioid Dispensing Rates, 2019. Drug Overdose: CDC Injury Center. Retrieved August 9, 2021. https://www.cdc.gov/drugoverdose/rxrate-maps/state2019.html
   Google Scholar
• Ciccarone, D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. International Journal on Drug Policy. https://doi.org/10.1016/j.drugpo.2019.01.010
   Google Scholar
• Cochran, G., Bruneau, J., Cox, N., & Gordon, A. J. (2020). Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Substance Abuse, 41(3), 269–274. https://doi.org/10.1080/08897077.2020.1787300
   PubMed Web of Science ®Google Scholar
• Council of State and Territorial Epidemiologists. (2021). Composite Index Scores. Jurisdiction Level Vulnerability Assessment Toolkit. Retrieved December 14, 2021, from https://resources.cste.org/JVAToolkit_Final_August2021/Home/Composite
   Google Scholar
• Din, A., & Wilson, R. (2020). Crosswalking ZIP codes to census geographies: Geoprocessing the U.S. Department of Housing & Urban Development’s ZIP code crosswalk files. Cityscape J Policy Dev Res, 22(1), 293–314. https://www.huduser.gov/portal/periodicals/cityscpe/vol22num1/ch12.pdf
   Google Scholar
• Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315(15), 1624–1645. https://doi.org/10.1001/jama.2016.1464
   PubMed Web of Science ®Google Scholar
• Ehrhart, A. L., Granek, E. F., Nielsen-Pincus, M., & Horn, D. A. (2020). Leftover drug disposal: Customer behavior, pharmacist recommendations, and obstacles to drug take-back box implementation. Waste Management (New York, N.Y.), 118, 416–425. https://doi.org/10.1016/j.wasman.2020.08.038
   PubMed Web of Science ®Google Scholar
• Furst, J. A., Mynarski, N. J., McCall, K. L., & Piper, B. J. (2022). Pronounced regional disparities in United States Methadone distribution. Annals of Pharmacotherapy, 56 (3), 271–279. https://doi.org/10.1177/10600280211028262
   PubMed Web of Science ®Google Scholar
• García, M. C. (2019). Opioid prescribing rates in nonmetropolitan and metropolitan counties among primary care providers using an electronic health record system — United States, 2014–2017. Morbidity and Mortality Weekly Report, 68 https://doi.org/10.15585/mmwr.mm6802a1
   Google Scholar
• Giraud, T. (n.d.). OSRM: Interface between R and the OpenStreetMap-Based Routing Service. Retrieved from https://CRAN.R-project.org/package=osrm
   Google Scholar
• Haffajee, R. L. (2019). Prescription drug monitoring programs — Friend or folly in addressing the opioid-overdose crisis? The New England Journal of Medicine, 381(8), 699–701. https://doi.org/10.1056/NEJMp1904714
   PubMed Web of Science ®Google Scholar
• Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E. (2019). Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Network Open, 2(6), e196373. https://doi.org/10.1001/jamanetworkopen.2019.6373
   PubMed Web of Science ®Google Scholar
• Haffajee, R. L., Mello, M. M., Zhang, F., Zaslavsky, A. M., Larochelle, M. R., & Wharam, J. F. (2018). Four states with robust prescription drug monitoring programs reduced opioid dosages. Health Affairs (Project Hope), 37(6), 964–974. https://doi.org/10.1377/hlthaff.2017.1321
   PubMed Web of Science ®Google Scholar
• Joudrey, P. J., Chadi, N., Roy, P., Morford, K. L., Bach, P., Kimmel, S., Wang, E. A., & Calcaterra, S. L. (2020). Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug and Alcohol Dependence. 211, 107968. https://doi.org/10.1016/j.drugalcdep.2020.107968
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. (2021). Mental Health & Substance Use. KFF. Retrieved March 26, 2021, from https://www.kff.org/state-category/mental-health/
   Google Scholar
• Keyes, K. M., Cerdá, M., Brady, J. E., Havens, J. R., & Galea, S. (2014). Understanding the rural–urban differences in nonmedical prescription opioid use and abuse in the United States. American Journal of Public Health, 104(2), e52–e59. https://doi.org/10.2105/AJPH.2013.301709
   PubMed Web of Science ®Google Scholar
• Kleinman, R. A. (2020). Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry, 77(11), 1163–1171. https://doi.org/10.1001/jamapsychiatry.2020.1624
   PubMed Web of Science ®Google Scholar
• Kolak, M. A., Chen, Y.-T., Joyce, S., Ellis, K., Defever, K., McLuckie, C., Friedman, S., & Pho, M. T. (2020). Rural risk environments, opioid-related overdose, and infectious diseases: A multidimensional, spatial perspective. The International Journal on Drug Policy, 85, 102727. https://doi.org/10.1016/j.drugpo.2020.102727
   PubMed Web of Science ®Google Scholar
• Langabeer, J. R., Stotts, A. L., Cortez, A., Tortolero, G., & Champagne-Langabeer, T. (2020). Geographic proximity to buprenorphine treatment providers in the U.S. Drug and Alcohol Dependence, 213, 108131. https://doi.org/10.1016/j.drugalcdep.2020.108131
   PubMed Web of Science ®Google Scholar
• Leppla, I. E., & Gross, M. S. (2020). Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2). Journal of Addiction Medicine, 14(4), e1–e3. https://doi.org/10.1097/ADM.0000000000000678
   PubMed Web of Science ®Google Scholar
• Liu, J. Y., Franklin, J. S., Gesek, F. A., & Anderson, J. C. (2020). Buyback program of unused prescription opioids in US rural communities, 2017–2018. American Journal of Public Health, 110(9), 1318–1324. https://doi.org/10.2105/AJPH.2020.305730
   PubMed Web of Science ®Google Scholar
• Luo, W., & Wang, F. (2003). Measures of spatial accessibility to health care in a GIS environment: Synthesis and a case study in the Chicago region. Environment and Planning. B, Planning & Design, 30(6), 865–884. https://doi.org/10.1068/b29120
   PubMed Web of Science ®Google Scholar
• Mattson, C. L., Tanz, L. J., Quinn, K., Kariisa, M., Patel, P., & Davis, N. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. MMWR. Morbidity and Mortality Weekly Report, 70(6), 202–207. https://doi.org/10.15585/mmwr.mm7006a4
   PubMed Web of Science ®Google Scholar
• Missouri Department of Health and Senior Services, Bureau of Reportable Disease Informatics. (2020). Missouri Opioid Overdose and Bloodborne Infection Vulnerability Assessments Retrieved September 28, 2020, from http://health.mo.gov/data/opioids/assessments.php
   Google Scholar
• National Center for Health Statistics, National Vital Statistics Rapid Release. (2020). 12-month provisional number of drug overdose deaths by drug or drug class, United States. Retrieved August 6, 2021, from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data
   Google Scholar
• O’Donnell, J. (2021). Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls — United States, 2019–2020. Morbidity and Mortality Weekly Report, 70(50)‌, 1740–1746. https://doi.org/10.15585/mmwr.mm7050e3
   Google Scholar
• Pena, E., & Ahmed, S. (2020). Time to revisit uneven policy in the United States for medication for opioid use disorder during COVID-19. Addiction (Abingdon, England), 115(10), 1978–1979. https://doi.org/10.1111/add.15143
   PubMed Web of Science ®Google Scholar
• Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. (2021). Federal Register. Retrieved August 11, 2021, from https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder
   Google Scholar
• Rickles, M., Rebeiro, P. F., Sizemore, L., Juarez, P., Mutter, M., Wester, C., & McPheeters, M. (2018). Tennessee’s in-state vulnerability assessment for a “rapid dissemination of human immunodeficiency virus or hepatitis C Virus infection” event utilizing data about the opioid epidemic. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 66(11), 1722–1732. https://doi.org/10.1093/cid/cix1079
   PubMed Web of Science ®Google Scholar
• Rigg, K. K., Monnat, S. M., & Chavez, M. N. (2018). Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. The International Journal on Drug Policy, 57, 119–129. https://doi.org/10.1016/j.drugpo.2018.04.011
   PubMed Web of Science ®Google Scholar
• Rodda, L. N., West, K. L., & LeSaint, K. T. (2020). Opioid overdose–related emergency department visits and accidental deaths during the COVID-19 pandemic. Journal of Urban Health, 97(6), 808–813. https://doi.org/10.1007/s11524-020-00486-y
   PubMed Web of Science ®Google Scholar
• Rosenblum, A., Cleland, C. M., Fong, C., Kayman, D. J., Tempalski, B., & Parrino, M. (2011). Distance traveled and cross-state commuting to opioid treatment programs in the United States. Journal of Environmental and Public Health, 2011, 1–10. https://doi.org/10.1155/2011/948789
   Google Scholar
• Sawyer, J. L., Shrestha, S., Pustz, J. C., Gottlieb, R., Nichols, D., Van Handel, M., Lingwall, C., & Stopka, T. J. (2021). Characterizing opioid-involved overdose risk in local communities: An opioid overdose vulnerability assessment across Indiana, 2017. Preventive Medicine Reports, 24, 101538. https://doi.org/10.1016/j.pmedr.2021.101538
   PubMedGoogle Scholar
• Sharareh, N., Hess, R., White, S., Dunn, A., Singer, P. M., & Cochran, J. (2020). A vulnerability assessment for the HCV infections associated with injection drug use. Preventive Medicine, 134, 106040. https://doi.org/10.1016/j.ypmed.2020.106040
   PubMed Web of Science ®Google Scholar
• Thomas, C. P., Doyle, E., Kreiner, P. W., Jones, C. M., Dubenitz, J., Horan, A., & Stein, B. D. (2017). Prescribing patterns of buprenorphine waivered physicians. Drug and Alcohol Dependence, 181, 213–218. https://doi.org/10.1016/j.drugalcdep.2017.10.002
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. (2018). American Community Survey, ACS 2014-2018 5-Year Estimates. Retrieved from https://www.census.gov/acs/www/data/data-tables-and-tools/data-profiles/
   Google Scholar
• Valenstein-Mah, H., Hagedorn, H., Kay, C. L., Christopher, M. L., & Gordon, A. J. (2018). Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Substance Abuse, 39(3), 286–288. https://doi.org/10.1080/08897077.2018.1509251
   PubMed Web of Science ®Google Scholar
• Van Handel, M. M., Rose, C. E., Hallisey, E. J., Kolling, J. L., Zibbell, J. E., Lewis, B., Bohm, M. K., Jones, C. M., Flanagan, B. E., Siddiqi, A.-E.-A., Iqbal, K., Dent, A. L., Mermin, J. H., McCray, E., Ward, J. W., & Brooks, J. T. (2016). County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. Journal of Acquired Immune Deficiency Syndromes (1999), 73(3), 323–331. https://doi.org/10.1097/QAI.0000000000001098
   PubMed Web of Science ®Google Scholar
• Wambeam, R., Gilbert, L., & Kilwein, T. (2018). Telling the story of opioid use in Wyoming. Wyoming Survey & Analysis Center, University of Wyoming. https://health.wyo.gov/wp-content/uploads/2018/03/Telling-the-Story-of-Prescription-Opioid-Use-in-Wyoming.pdf
   Google Scholar
• Wang, F., & Luo, W. (2005). Assessing spatial and nonspatial factors for healthcare access: towards an integrated approach to defining health professional shortage areas. Health & Place, 11(2), 131–146. https://doi.org/10.1016/j.healthplace.2004.02.003
   PubMed Web of Science ®Google Scholar
• Wendt, D. C., Marsan, S., Parker, D., Lizzy, K. E., Roper, J., Mushquash, C., Venner, K. L., Lam, A., Swansburg, J., Worth, N., Sorlagas, N., Quach, T., Manoukian, K., Bernett, P., & Radin, S. M. (2021). Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada. Journal of Substance Abuse Treatment, 121, 108165. https://doi.org/10.1016/j.jsat.2020.108165
   PubMed Web of Science ®Google Scholar
• Wyoming Department of Health. (n.d.). Drug Overdose Data. Wyoming Department of Health. Retrieved August 11, 2021, from https://health.wyo.gov/publichealth/prevention/substanceabuseandsuicide/publications-and-reports/non-fatal-drug-overdoses/
   Google Scholar
• Zoorob, M. (2019). Fentanyl shock: The changing geography of overdose in the United States. The International Journal on Drug Policy, 70, 40–46. https://doi.org/10.1016/j.drugpo.2019.04.010
   PubMed Web of Science ®Google Scholar